Spectral AI, Inc. (MDAI) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Spectral AI, Inc. is an emerging growth company and smaller reporting company focused on predictive medical diagnostics using artificial intelligence (AI). The company develops the DeepView System, a multispectral imaging device combined with AI algorithms to assess burn wound healing potential. The reporting period covers the fiscal year ended December 31, 2025. The company has not yet generated commercial product revenue; its operations are primarily funded by U.S. government contracts, specifically with the Biomedical Advanced Research and Development Authority (BARDA) and the Defense Health Agency (DHA).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Research & Development Revenue | $19.65 million | $29.58 million |
| Gross Profit | $8.93 million | $13.27 million |
| Gross Margin | 45.4% | 44.9% |
| Operating Loss | ($8.60 million) | ($6.58 million) |
| Net Loss | ($7.57 million) | ($15.16 million) |
| Cash and Cash Equivalents (Year End) | $15.39 million | $5.16 million |
| Working Capital | ($1.17 million) | N/A |
| Accumulated Deficit | ($55.80 million) | ($48.23 million) |
| Notes Payable (Total) | $8.39 million | $2.79 million |
Note: Net loss improved significantly in 2025 primarily due to a $3.25 million gain from the change in fair value of warrant liabilities, offsetting higher operating losses.
Material Changes vs. Prior Period
- Revenue Decline: R&D revenue decreased 33.6% to $19.65 million, driven by a 36.6% drop in BARDA contract revenue ($17.70 million vs. $27.90 million) as the base phase of the contract neared completion. Revenue from other U.S. government authorities increased slightly by 16.2%.
- Cost Reduction: Cost of revenue decreased 34.2% to $10.73 million, aligning with reduced development activity. General and administrative expenses decreased 11.7% to $17.53 million due to reduced headcount and non-revenue generating R&D costs.
- Financing Activity: The company raised significant capital in 2025, including an $8.5 million initial drawdown from the Avenue Financing debt facility and $7.6 million from the Hudson Bay equity financing. Net cash provided by financing activities was $20.12 million.
- Warrant Liability Volatility: The company recognized a $3.25 million gain on the change in fair value of warrant liabilities in 2025, compared to a $4.63 million loss in 2024, significantly impacting the bottom line.
Guidance, Outlook, and Risks
Outlook and Milestones:
- Regulatory Status: The company submitted a De Novo application to the FDA for its burn indication in June 2025 and expects clearance in the first half of 2026. It holds UKCA marking for the UK market and expects to begin commercial sales there in 2026.
- Government Funding: On March 18, 2026 (subsequent to year-end), the company announced a BARDA contract modification advancing $31.7 million, including a no-cost extension and acceleration of the next phase.
- Liquidity: Management believes current cash, government contracts, and financing facilities are sufficient to fund operations for at least 12 months beyond the filing date.
Key Risks and Contingencies:
- Government Dependence: The company is highly dependent on BARDA and DHA contracts. Loss or reduction of this funding would materially harm operations. The BARDA contract is not guaranteed to be extended.
- Regulatory Uncertainty: There is no assurance the FDA will grant De Novo classification. Delays in clinical trials or regulatory review could impair the business plan.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting related to the accounting for complex equity arrangements, the financial statement close process, and accruals. Remediation efforts are ongoing.
- Profitability: The company has incurred significant losses since inception and may not achieve profitability. Future capital raises may be necessary and could result in dilution.
Investor Verification Checklist
- BARDA Contract Status: Verify the specific terms and remaining value of the BARDA PBS contract and the likelihood of option exercises.
- FDA De Novo Timeline: Confirm the current status of the De Novo application submitted in June 2025 and any FDA feedback received.
- Internal Control Remediation: Review the progress of remediation plans for the identified material weaknesses in financial reporting controls.
- Debt Covenants: Examine the covenants and milestone requirements for the Avenue Financing (specifically the $7.0 million equity raise and FDA clearance required for the second tranche).
- Warrant Liability Valuation: Assess the sensitivity of the warrant liability fair value to changes in stock price and volatility, given its significant impact on net income.